Objectif "Development of advanced therapeutics based on non-small molecule drugs for brain diseases is an area of intense research. Experimental work using viral vector-mediated in vivo gene therapy showed great potential as a competitive therapeutic strategy for clinical use in neurodegenerative diseases. AAV vectors are now in early clinical trials stage for treatment of Parkinson’s disease. Although it is deemed very important to have controlled expression in the brain, none of the currently tested strategies have implemented an approach that can be exogenously controlled. Regulation of the therapeutic intervention is important not only for safety reasons but has important implications for tuning the delivery of the therapeutic molecule to the individual needs of the patients, i.e. personalizing their treatment. The core of this proof-of-concept application is to develop a novel gene regulation system as a product for clinical use in patients with Parkinson’s disease. The applicant has assembled a strong team of experts that can take this exciting idea that has spun out of his ERC-funded research to an early business strategy and bridge to commercialization. The work will include filing of new IP, a proactive use of novelty search, formation of a dedicated start-up company for handling the new IPR as well as in-licensing of related IP, and sketching a path towards commercialization via obtaining regulatory authorization, investigation of strategies for large-scale production of the product." Champ scientifique medical and health sciencesmedical biotechnologygenetic engineeringgene therapymedical and health sciencesbasic medicineneurologyparkinson Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) ERC-OA-2012-PoC - European Research Council ERC Proof of Concept Appel à propositions ERC-2012-PoC Voir d’autres projets de cet appel Régime de financement CSA-SA(POC) - Supporting action (Proof of Concept) Institution d’accueil MAX IV Laboratory, Lund University Contribution de l’UE € 42 800,00 Adresse Paradisgatan 5c 22100 LUND Suède Voir sur la carte Région Södra Sverige Sydsverige Skåne län Type d’activité Higher or Secondary Education Establishments Contact administratif Michael De Rooy (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Bénéficiaires (2) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire MAX IV Laboratory, Lund University Suède Contribution de l’UE € 42 800,00 Adresse Paradisgatan 5c 22100 LUND Voir sur la carte Région Södra Sverige Sydsverige Skåne län Type d’activité Higher or Secondary Education Establishments Contact administratif Michael De Rooy (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée BRAINGENE AB Suède Contribution de l’UE € 107 200,00 Adresse SANDGATAN 14 SE 223 50 LUND Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Michael Wiegert (Mr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée
